淋病控制性人类感染研究专家共识
国际多学科利益相关方研讨会于2025年3月在牛津召开,通过结构化讨论回顾淋病控制性人类感染研究(CHIS)现状并建立共识标准。共识肯定使用FA1090等特征明确菌株的CHIS价值,推荐基于风险的标准化菌株制造与质量保证,支持扩展至女性生殖解剖人群等新人群,认为CHIS可加速疫苗和抗菌药物开发。
要点
- CHIS使用FA1090等特征明确菌株仍有价值,新型菌株需仔细选择和表征。
- 推荐基于风险的标准化接种物制造和质量保证,提高可重复性和可扩展性。
- 扩展至女性生殖解剖等新人群有科学价值,但需严格伦理和安全评估。
核心结论
- 淋病CHIS是未充分利用但有价值的研究工具,有望加速淋病转化研究。
- 在强伦理监督、社区参与和国际合作下,扩大和协调CHIS可显著推进预防和治疗策略。
研究设计与样本
- 2025年3月在英国牛津召开国际多学科利益相关方研讨会,通过结构化讨论回顾CHIS活动、确定研究优先事项并建立共识标准。
主要发现
- 共识强调使用FA1090等特征明确菌株的CHIS持续有价值,同时支持仔细选择和表征新型菌株。
- 推荐采用标准化、基于风险的接种物制造和质量保证方法,以增强可重复性和可扩展性。
- 将CHIS扩展至额外解剖部位和新人群(包括女性生殖解剖个体)被认为具有科学价值,但需仔细的伦理和安全评估。
- CHIS被认为独特地 positioned 通过早期疗效评估、保护相关物识别及治疗和预防策略优化来推进疫苗和抗菌药物开发。
临床怎么用
- 临床医生可关注CHIS作为加速淋病疫苗和抗菌药物开发的工具,尤其用于早期疗效评估和保护相关物识别。
- 在涉及女性生殖解剖个体等新人群的CHIS扩展中,需重视伦理和安全评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gonorrhoea, a bacterial sexually transmitted infection caused by Neisseria gonorrhoeae, is a major global public health concern due to rising incidence and increasing antimicrobial resistance. Absence of a licensed vaccine and limitations of animal models have impeded progress in the understanding of pathogenesis, immunity and development of novel therapeutics and vaccines. Controlled human infection studies (CHIS) offer a powerful approach to accelerate vaccine and antimicrobial development and improve understanding of host-pathogen interactions. METHODS: An international, multidisciplinary stakeholder workshop was convened in Oxford, UK (March 2025) to review current gonorrhoea CHIS activity, define research priorities and establish consensus standards for future studies through structured discussion. RESULTS: Consensus highlighted the continued value of CHIS with well-characterised strains such as FA1090, while supporting careful selection and characterisation of novel strains. Standardised, risk-based approaches to inoculum manufacture and quality assurance were recommended to enhance reproducibility and scalability. Expansion of CHIS to include additional anatomical sites and novel populations, including individuals with female reproductive anatomy, was identified as scientifically valuable but requiring careful ethical and safety evaluation. CHIS were recognised as uniquely positioned to advance vaccine and antimicrobial development by enabling early efficacy assessment, identification of correlates of protection and optimisation of treatment and prevention strategies. CONCLUSIONS: Gonorrhoea CHIS are an underutilised but valuable research tool with potential to accelerate translational research against gonorrhoea. With robust ethical oversight, community engagement and international collaboration, expanded and harmonised CHIS could substantially advance prevention and treatment strategies.
引用
- Hodgson SH, McCarthy JS, Duncan JA, et al. Expert Consensus on Controlled Human Infection Studies for Gonorrhoea. J Infect Dis. 2026. PMID: 42800054. doi:10.1093/infdis/jiag486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。